ESSA Pharma Inc Market Cap ($9.52 Million)
Market Cap & Net Worth: ESSA Pharma Inc (EPIX)
ESSA Pharma Inc market cap. ESSA Pharma Inc (NASDAQ:EPIX) has a market capitalization of $9.52 Million ($9.52 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27048 globally and #5620 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ESSA Pharma Inc's stock price $0.20 by its total outstanding shares 47308394 (47.31 Million). Also see EPIX operating cash flow for how efficiently the company converts equity into cash flow.
ESSA Pharma Inc Market Cap History (2015–2025)
ESSA Pharma Inc market cap history from 2015 to 2025. Data shows change from $4.02 Billion to $9.52 Million (-47.57% CAGR). Check EPIX live share price for real-time trading data and today's change.
Index Memberships
ESSA Pharma Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #756 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #2470 of 3165 |
Weight: ESSA Pharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ESSA Pharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ESSA Pharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ESSA Pharma Inc (EPIX) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
9548883.21x
ESSA Pharma Inc's market cap is 9548883.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.07 Billion | $217.00 | -$13.14 Million | 9548883.21x | N/A |
Competitor Companies of EPIX by Market Capitalization
Companies near ESSA Pharma Inc in the global market cap rankings as of November 5, 2026. Also see ESSA Pharma Inc total assets for a full breakdown of the balance sheet.
Key companies related to ESSA Pharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of ESSA Pharma Inc (2015–2025)
Market capitalization of ESSA Pharma Inc from 2015 to today. Between 2015 and today, ESSA Pharma Inc's market cap moved from $4.02 Billion to $ 9.52 Million, with a yearly change of -47.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $9.52 Million | -88.76% |
| 2024 | $84.68 Million | -72.88% |
| 2023 | $312.24 Million | +161.90% |
| 2022 | $119.22 Million | -82.25% |
| 2021 | $671.78 Million | +19.03% |
| 2020 | $564.39 Million | +116.91% |
| 2019 | $260.20 Million | +161.90% |
| 2018 | $99.35 Million | -52.12% |
| 2017 | $207.49 Million | -89.99% |
| 2016 | $2.07 Billion | -48.47% |
| 2015 | $4.02 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 7th, 2026 the market cap of ESSA Pharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.52 Million USD |
| MoneyControl | $9.52 Million USD |
| MarketWatch | $9.52 Million USD |
| marketcap.company | $9.52 Million USD |
| Reuters | $9.52 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ESSA Pharma Inc
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada. As of October 9, 2025, ESSA Pharma Inc. operates as a subsidiary of Alexis Bio, Inc.